Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 1551 • ACR Convergence 2023
Measurement of Sinonasal Disease Activity in Granulomatosis with Polyangiitis
Roger Yang¹, Ellen Romich², Shubhasree Banerjee³, Naomi Amudala³, Peter Merkel³, Joshua Baker³ and Rennie Rhee³, ¹University of Pennsylvania, Montréal, QC, Canada, ²Hospital of the University of Pennsylvania, Media, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: In granulomatosis with polyangiitis (GPA), sinonasal inflammation can be severe and significantly impact quality of life. Little is known about the most effective local…
Abstract Number: 2383 • ACR Convergence 2023
Clinical Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Dual Positive Anti-Neutrophil Cytoplasmic Antibody and Anti-Glomerular Basement Membrane Antibody: A Single Center Experience
Zaina Shahid, Michael Lucke and Swati Arora, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Knowledge of disease characteristics and long-term outcomes of dual-positive patients (DPP) exhibiting anti-neutrophil cytoplasmic antibodies (ANCA) and anti-glomerular basement membrane (GBM) antibodies is limited…
Abstract Number: 0679 • ACR Convergence 2023
Long-term Safety of Rituximab (Mabthera) in Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA): Rituximab Surveillance Study in VASculitis (RIVAS)
Lisa Uchida¹, Dr Rachel Jones², Rona Smith¹, Claudia Loechel³, Maria King³, Marianna Nodale⁴, Simon Bond⁴, Raashid Luqmani⁵, David Gray⁵, Joe Barrett⁵ and David Jayne⁶, ¹Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ²Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom, ³Vasculitis and Lupus Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, ⁴Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, ⁵Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁶University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Rituximab is a first-line treatment for remission induction and the prevention of relapse in ANCA-associated vasculitis (AAV). There is a paucity of real-world data…
Abstract Number: 0856 • ACR Convergence 2023
Dupilumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Berengere Molina¹, Roberto Padoan², Maria Letizia Urban³, Pavel Novikov⁴, Marco Caminati⁵, Camille Taillé⁶, Antoine Néel⁷, Laurence Bouillet⁸, Paolo Fraticelli⁹, Nicolas Schleinitz¹⁰, Christine Christides¹¹, Laura Moi¹², Bertrand Godeau¹³, Ann Knight¹⁴, Jan Walter Schroeder¹⁵, Sylvain Marchand-Adam¹⁶, Helder Gil¹⁷, Vincent Cottin¹⁸, Cécile-Audrey Durel¹⁹, Elena Gelain²⁰, Boris Lerais²¹, Marc Ruivard²², Matthieu Groh²³, Maxime Samson²⁴, Luca Moroni²⁵, Jens Thiel²⁶, Anna Kernder²⁷, Jan Willem Cohen Tervaert²⁸, Giulia Costanzo²⁹, Marco Folci³⁰, Sonia Rizzello³¹, Pascal Cohen³², Giacomo Emmi³³ and Benjamin Terrier³⁴, ¹Cochin Hospital, Paris, France, ²Department of Medicine DIMED, University of Padova, Padova, Italy, ³Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁴Sechenov First Moscow State Medical University, Moscow, Russia, ⁵University of Verona, Verona, Italy, ⁶AP-HP, Bichat Hospital, Reference Center for Rare Pulmonary Diseases and University of Paris Cité, Inserm 1152, Paris, France, ⁷CHU Nantes, Nantes, France, ⁸Internal medicine department, Grenoble University Hospital, Grenoble, France, ⁹University Hospital Ospedali Riuniti, Ancona, Italy, ¹⁰Aix Marseille university, AP-HM, Marseille, France, ¹¹Avignon Hospital, Avignon, France, ¹²Valais Hospital, Sion, Switzerland, ¹³CHU Henri Mondor, Créteil, France, ¹⁴Uppsala University, Uppsala, Sweden, ¹⁵ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ¹⁶CHRU Tours, service de pneumologie et d'explorations fonctionnelles respiratoires, Tours, France, ¹⁷CHU Besancon, Besançon, France, ¹⁸Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ¹⁹CHU Lyon, Lyon, France, ²⁰Meyer Children's Hospital, Florence, Italy, ²¹Brest University Hospital, Brest, France, ²²CHU Clermont Ferrand, Clermont Ferrand, France, ²³National Referral Center for Hypereosinophilic Syndrome (CEREO), Hôpital Foch, Suresnes, France, ²⁴Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²⁵San Raffaele Scientific Institute, Milan, Italy, ²⁶University Hospital Freiburg, Freiburg, Germany, ²⁷Heinrich-Heine-University Düsseldorf, Dusseldorf, Germany, ²⁸University of Alberta, Edmonton, AB, Canada, ²⁹University of Cagliari, Monserrato, Italy, ³⁰Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy, ³¹Careggi University Hospital, Florence, Italy, ³²CHU Cochin, Paris, France, ³³University of Florence, Florence, Italy, ³⁴Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an ANCA-associated vasculitides characterized by asthma, blood and tissue eosinophilia and systemic manifestations. Glucocorticoids (GCs)-dependent asthma and/or disabling…
Abstract Number: 1584 • ACR Convergence 2023
Effect of Trimethoprim Sulfamethoxazole Prophylaxis on Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: A Population-Based Study
Arielle Mendel¹, Hassan Behlouli², Evelyne Vinet¹, Jeffrey Curtis³ and Sasha Bernatsky², ¹McGill University Health Centre, Montréal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Infections during treatment of ANCA-associated vasculitis (AAV) lead to excess mortality. Trimethoprim sulfamethoxazole (TMP-SMX), recommended for pneumocystis jirovecii pneumonia (PJP) prophylaxis, has broad antimicrobial…
Abstract Number: 2384 • ACR Convergence 2023
Major Cardiovascular Adverse Events in Patients with ANCA Vasculitis Compared with Hypertension Control Group
Lisa Rosenberg¹, Larabe Farrukh¹, Simrin Kooner¹, Moiz Ehtesham¹, Sumbal Wajid¹, Ruben Peredo-Wende² and Shannon Murawski¹, ¹Albany Medical Center, Albany, NY, ²Stratton VA Medical Center, Albany, NY
Background/Purpose: Vascular damage from inflammation in ANCA vasculitis leads to a sustained procoagulant state causing accelerated atherosclerosis. A population-based cohort study found that the risk…
Abstract Number: 0680 • ACR Convergence 2023
Risk Factors for Hypogammaglobulinemia and Association with Relapse and Severe Infections in ANCA-Associated Vasculitis: A Retrospective Single-Centre Cohort Study
Johanne LIBERATORE¹, Yann Nguyen², Jerome HADJADJ³, Pascal Cohen⁴, Luc Mouthon⁵, Xavier Puéchal⁶, Loic Guillevin⁷ and Benjamin Terrier⁸, ¹Centre Hospitalier ANGOULEME, Angouleme, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³Cochin Hospital, Paris, France, ⁴CHU Cochin, Paris, France, ⁵Hopital Cochin - Paris University, Paris, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ⁷University Paris Descartes, Paris, France, ⁸Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: B-cell depletion induced by rituximab (RTX) in ANCA-associated vasculitis (AAV) is a risk factor for hypogammaglobulinemia. Aggregating data on the kinetics of gammaglobulin levels…
Abstract Number: 0857 • ACR Convergence 2023
Change in Albuminuria in Patients with ANCA-Associated Vasculitis Treated with Avacopan
Duvuru Geetha¹, Frank Cortazar², alexandre Karras³, Annette Bruchfeld⁴, Huibin Yue⁵, Peter Merkel⁶ and David Jayne⁷, ¹Johns Hopkins University, Baltimore, MD, ²New York Nephrology, Watervliet, NY, ³HEGP - APHP, Paris, France, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Urinary albumin:creatinine ratio (UACR) is an important biomarker of active glomerulonephritis, a common complication of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). In most glomerular…
Abstract Number: 1619 • ACR Convergence 2023
Receipt of Antimicrobial Prophylaxis in U.S. Medicare Beneficiaries Initiating Immunosuppressive Medications for ANCA Vasculitis
Carolyn Thorpe, Ryan Hickson, Sherrie Aspinall, Vimal Derebail, Xinhua Zhao, Joshua Thorpe, Binxin Cao, Alexa Ehlert, Ronald Falk and Susan Hogan, University of North Carolina, Chapel Hill, NC
Background/Purpose: Infections are the leading cause of hospitalization and mortality in patients with ANCA vasculitis (AV). Multiple AV treatment guidelines recommend antimicrobial prophylaxis during treatment…
Abstract Number: 2385 • ACR Convergence 2023
Risk of Major Adverse Cardiovascular Events in ANCA-associated Vasculitis
Jon Idoate¹, Morgane Mourguet¹, Thomas Villeneuve¹, Grégoire Prevot¹, Laurent Guilleminault², Ribes David¹, Stan Faguer¹, Antoine Huart¹, Dominique Chauveau¹, Laurent Alric¹, Martin Michaud¹, Laurent Sailler¹, Sébastien De Almeida Chavez¹, Emmanuelle Mouchon¹, Olivier Lairez¹ and Gregory Pugnet³, ¹CHU Toulouse, Toulouse, France, ²Department of respiratory and allergic diseases, Toulouse University Hospital Center, Toulouse, France, ³CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France
Background/Purpose: The aim of this study was to investigate the risk of major adverse cardiovascular events (MACE) in patients with ANCA-associated vasculitis (AAV). Methods: We…
Abstract Number: 0681 • ACR Convergence 2023
Real-World Outcomes for Remission Induction in Working-Age Adults with Severe Anti-Neutrophil Cytoplasmic Antibody-associated Vasculitis
Itay Marmor¹, Katelin Nickel², Matthew Keller², Guy Hazan³, Kevin Baszis⁴, Anthony French⁵ and Mary Hartman², ¹Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ²Washington University in St. Louis, St. Louis, MO, ³Soroka University Medical Center, Beer Sheva, Israel, ⁴Washington Univ in St. Louis School of Medicine, St. Louis, MO, ⁵Washington University School of Medicine, St. Louis, MO
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), often manifests with life-threatening complications. Cyclophosphamide (CYC) and rituximab…
Abstract Number: 0858 • ACR Convergence 2023
Randomized, Controlled, Double-Blind Trial on the Impact of Rosuvastatin on Sublinical Markers of Atherosclerosis in Patients with ANCA-Associated Vasculitis
Benjamin Terrier¹, Gregory Pugnet², Marie-Emmanuelle Sirieix³, Thomas Quemeneur⁴, Xavier Puéchal⁵, Francois Maurier⁶, Antoine Néel⁷, YGAL BENHAMOU⁸, Bernard Bonnotte⁹, Jean Schmidt¹⁰, Adrien Michon³, Antoine Baudet¹¹, Pierre Charles¹², Fleur Cohen¹³, Claire De Moreuil¹⁴, Emanuelle Dernis¹⁵, Pauline Belenotti¹⁶, Marc Ruivard¹⁷, Olivier Aumaitre¹⁸, Olivier Fain¹⁹, Raphaele Seror²⁰, Cécile-Audrey Durel²¹, Noémie Jourde-Chiche²², Estibaliz Lazaro²³, Gilles Chironi²⁴, Guillaume Armengol²⁵, Jeremy Bellien²⁵, Philippe Ravaud²⁶, Gabriel Baron²⁶ and Loic Guillevin²⁷, ¹Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France, ²CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ³HEGP, Paris, France, ⁴CH Valenciennes, Valenciennes, France, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ⁶Hôpitaux privés de Metz, Vaux / Frankreich, France, ⁷CHU Nantes, Nantes, France, ⁸rouen university hospital, Rouen, France, ⁹Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ¹⁰CHU Amiens, Amiens, France, ¹¹CH Annecy, Annecy, France, ¹²Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, ¹³Sorbonne Université, Paris, France, ¹⁴CHU de Brest, Brest, France, ¹⁵CH Le Mans, Le Mans, France, ¹⁶CHU Marseille, Marseille, France, ¹⁷CHU Clermont Ferrand, Clermont Ferrand, France, ¹⁸CHU Saint Antoine, Paris, France, ¹⁹Hopital SAINT ANTOINE APHP, Paris, France, ²⁰University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ²¹CHU Lyon, Lyon, France, ²²AP-HM, Marseille, France, ²³Bordeaux Hospital University, Pessac, France, ²⁴Monaco, Monaco, Monaco, ²⁵CHU Rouen, Rouen, France, ²⁶Paris Cité University, Paris, France, ²⁷University Paris Descartes, Paris, France
Background/Purpose: Despite more effective therapeutic strategies in ANCA-associated vasculitis (AAV), there is still a significant risk of morbidity and mortality, mainly due to infection, and…
Abstract Number: 1863 • ACR Convergence 2023
Immune-mediated Hypertrophic Pachymeningitis: Focusing on the Localization and Volume of Thickened Dura Mater Lesion
Yasuhiro Shimojima¹, Junji Ikeda² and Yoshiki Sekijima¹, ¹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ²Department of Medicine (Neurologu and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Background/Purpose: Hypertrophic pachymeningitis (HP) is a rare inflammatory neurological disorder characterized by the thickened dura mater with extensive tissue fibrosis and immune-mediated inflammation. Notably, headaches…
Abstract Number: 2386 • ACR Convergence 2023
Impact of ANCA Specificity on Risk of Major Adverse Cardiovascular Events in ANCA-associated Vasculitis
Jon Idoate¹, Morgane Mourguet¹, Ribes David¹, Stan Faguer¹, Antoine Huart¹, Dominique Chauveau¹, Thomas Villeneuve¹, Grégoire Prevot¹, Laurent Guilleminault², Emmanuelle Mouchon¹, Laurent Balardy¹, Laurent Sailler¹, Sébastien De Almeida Chavez¹, Laurent Alric¹, Martin Michaud¹, Olivier Lairez¹ and Gregory Pugnet³, ¹CHU Toulouse, Toulouse, France, ²Department of respiratory and allergic diseases, Toulouse University Hospital Center, Toulouse, France, ³CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France
Background/Purpose: The aim of this study was to investigate the relationship between ANCA specificity and the risk of major adverse cardiovascular events (MACE) in patients…
Abstract Number: 0682 • ACR Convergence 2023
Avacopan in ANCA-associated Vasculitis Received Intensified Induction Therapy with Cyclophosphamide Plus Rituximab – Retrospective Case Serial of 12 Patients
Gunter Assmann¹, Christoph Rittich¹, Frank Neumann², Udo Kellner³, Ryszard Turkiewicz⁴, Joerg Radermacher⁵, Peter Lamprecht⁶ and Björn Tampe⁷, ¹RUB University Hospital Minden - Rheumatology, Minden, Germany, ²Jose Carreras Center Saarland, Homburg, Germany, ³RUB University Hospital Minden - Pathology, Minden, Germany, ⁴RUB University Hospital Minden - Pulmonology, Minden, Germany, ⁵RUB University Hospital Minden - Nephrology, Minden, Germany, ⁶University Hospital Luebeck - Schleswig-Holstein, Luebeck, Germany, ⁷University Clinic department Goettingen - Nephrology, Goettingen, Germany
Background/Purpose: The orally administered C5a receptor inhibitor avacopan is approved for the therapy of ANCA-associated vasculitis (AAV) in combination with rituximab or cyclophosphamide and shows…

« Previous Page
1
…
5
6
7
8
9
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].